Opiate modulation of gastrointestinal motility and the actions of trimebutine

STEPHEN M COLLINS, MB, BS, FRCP(UK), FRCPC, EDWIN E DANIEL, PHD

SM COLLINS, EE DANIEL. Opiate modulation of gastrointestinal motility and the actions of trimebutine. Can J Gastroenterol 1991;5(5):185-193. Trimebutine is an opiate ligand that interacts with the μ, δ and κ receptor subclasses with approximately equal affinity. Since opiate receptors are widely distributed in the gut, and because opiate receptor subtypes may be involved in excitatory or inhibitory control mechanisms, trimebutine has an unusual profile of action that cannot be predicted on the basis of experience with other synthetic opiates such as codeine, morphine or loperamide. Trimebutine influences motility throughout the gastrointestinal tract. The effect of trimebutine on the lower esophageal sphincter raises the possibility of a beneficial role in the treatment of gastroesophageal reflux disease. The ability of trimebutine to promote propulsive activity in the fasting and postprandial small intestine offers novel therapeutic approaches to the treatment of motility disorders, including postoperative ileus and pseudo-obstruction. Finally, the effect of the drug on the colon supports the use of trimebutine in irritable bowel syndrome patients who have constipation due to colonic inertia.

Key Words: Gastrointestinal motility, Muscle, Nerve, Opiates, Pharmacology, Receptors, Trimebutine

Opiacés et motilité gastrointestinale – Les effets de la trimébutine

RESUME: La trimébutine est un ligand opiacé qui agit avec une affinité à peu près égale au niveau des sous-types de récepteurs μ, δ et κ. Parce que les récepteurs opiacés abondent dans l’intestin et parce que les sous-types de récepteurs opiacés participent peut-être aux mécanismes de régulation excitateurs et inhibiteurs, la trimébutine interagit avec des opiate récepteurs intestinaux. Le bénéfice du traitement des troubles de la motilité par la trimébutine suggère des approches thérapeutiques nouvelles pour le traitement de ces troubles, y compris l’œdème post-chirurgical et la pseudo-occlusion intestinale. Enfin, l’effet de la trimébutine sur le côlon soutiendra l’utilisation de cette substance dans les patients atteints de syndrome de l’entérite irritable à cause de la constipation colique.

T R I M E B U T I N E (2-DIMETHYLAMINO-2-phenylbutyl - trimethoxybenzoate maleate; Modulon, Jouveinal) has been used to treat several manifestations of functional bowel disease, including idiopathic (nonulcer) dyspepsia (1), abdominal pain (2) and altered bowel habits (3). The therapeutic benefit of trimebutine in these disorders is believed to be due to its effect on motility (4).

The mechanism of action of trimebutine has only recently become understood. In 1987 in vitro studies provided definitive evidence that trimebutine interacts with opiate receptors in the brain and myenteric plexus (5,6), and it is reasonable to assume that many of the actions of trimebutine on motility are mediated by opiate receptors. In order to understand the effects of trimebutine on motility, it is first necessary to review briefly opiate receptor pharmacology, as well as some principles that underlie the control of gastrointestinal motility.

OPIATE RECEPTORS AND MOTILITY

Classification of opiate receptors: Naturally occurring opiate peptides are widely distributed in the brain, autonomic nervous system and gut, and in-
trimébutine présente un mécanisme d'action qu'on ne peut prévoir d'après l'expérience qu'on a des autres opiacés synthétiques tels que la codéine, la morphine et la lopéramide. La trimébutine renforce la mobilité des voies digestives. Son effet sur le sphincter oesophagien inférieur laisse entrevoir un rôle bénéfique dans le traitement du reflux gastro-oesophagien. Le fait que la trimébutine stimule la motricité du grêle à jeun et après les repas offre de nouvelles possibilités dans le traitement des troubles de la mobilité – iléus post-opératoire et pseudo-obstruction, entre autres. Finalement, l'action du médicament sur le côlon encourage à prescrire la trimébutine aux patients souffrant du syndrome du côlon irritable et de constipation aigüe.

**TABLE 1**
The binding of ligands to opiate receptors in guinea pig brain and myenteric plexus

<table>
<thead>
<tr>
<th>Brain</th>
<th>DHM (µ)</th>
<th>DADLE (δ)</th>
<th>EKC (κ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimebutine</td>
<td>212±40</td>
<td>1747±245</td>
<td>1456±120</td>
</tr>
<tr>
<td>Dimethyl-trimebutine</td>
<td>345±90</td>
<td>1080±330</td>
<td>1372±157</td>
</tr>
<tr>
<td>Morphine</td>
<td>7±1</td>
<td>152±52</td>
<td>128±15</td>
</tr>
<tr>
<td>DADLE</td>
<td>8±1</td>
<td>1±0</td>
<td>2187±688</td>
</tr>
<tr>
<td>EKC</td>
<td>1±0</td>
<td>4±1</td>
<td>0.5±0</td>
</tr>
</tbody>
</table>

Myenteric plexus

<table>
<thead>
<tr>
<th>DAGO (µ)</th>
<th>DSLET (δ)</th>
<th>EKC (κ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimebutine</td>
<td>1609±389</td>
<td>1193±304</td>
</tr>
<tr>
<td>Dimethyl-trimebutine</td>
<td>1924±708</td>
<td>2196±228</td>
</tr>
<tr>
<td>Morphine</td>
<td>7±1</td>
<td>578±178</td>
</tr>
<tr>
<td>DSLET</td>
<td>347±86</td>
<td>23±7</td>
</tr>
<tr>
<td>EKC</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Shown are the 50% inhibitory concentration values (in nM) for the ability of various opiates to displace radioligands from synaptosomes from guinea pig brain or myenteric plexus. The radioligands are shown on the horizontal axis at the top of the table. DADLE (D-Ala²-D-Leu⁷) enkephalin, a δ-selective ligand; DAGO (D-Ala²-MePhe⁴-Gly⁵-OL) enkephalin, a µ-selective ligand; DHM Dihydromorphine, a µ-selective ligand; DSLET (D-Ser⁵-D-Leu⁶-L-Thr⁷) enkephalin, a δ-selective ligand; EKC Ethylketocyclazocine, a κ-selective ligand.

**TABLE 2**
Differences between trimebutine and morphine

<table>
<thead>
<tr>
<th>Opiate selectivity</th>
<th>Trimebutine (µ, δ, κ)</th>
<th>Morphine (µ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower esophageal sphincter</td>
<td>Increases</td>
<td>Decreases</td>
</tr>
<tr>
<td>pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal colonic motility</td>
<td>No effect</td>
<td>Stimulates</td>
</tr>
<tr>
<td>Colonic transit</td>
<td>Accelerates</td>
<td>Slows</td>
</tr>
<tr>
<td>Clinical effect</td>
<td>Regulates</td>
<td>Constipates</td>
</tr>
</tbody>
</table>

**THE ROLE OF DIYNAPINE:**

Dyneapine provides an example of the selective actions of morphine. It acts on specific receptors, without altering the hormonal environment, without affecting intestinal transit and without causing constipation. Yet, it reduces intestinal transit time, increases motility, and improves the treatment of symptoms associated with gastro-intestinal motility. The effect of dynapine on gastro-intestinal motility is shown to be dose-dependent, with the highest dose providing the best results. This selective action of dynapine on gastrointestinal motility is unique and provides a new perspective on the treatment of gastrointestinal disorders.

**THE STATE OF THE GUT:**

The final determinant of gastrointestinal motility is largely influenced by the interplay of multiple factors, including both intrinsic and extrinsic signals. The intrinsic factors include the neural and endocrine signals that regulate the enteric nervous system, while the extrinsic factors include the effects of dietary and environmental stimuli. The complex interplay of these factors contributes to the dynamic and variable nature of gastrointestinal motility.

**FACTORS THAT INFLUENCE THE ACTIONS OF OPIATES ON MOTILITY:**

In addition to the intrinsic properties of the opiate (i.e., selectivity for specific receptor subtypes), the effect of an opiate on gastrointestinal motility will be affected by several other factors. These are important not only in the context of therapy, but also in the interpretation of data derived from in vivo and in vitro studies of the mechanisms of actions of opiate ligands. The state of the gut is a critical factor in determining the efficacy of an opiate in treating gastrointestinal disorders. The gut's physiological state, including its intrinsic and extrinsic factors, will influence the way in which an opiate acts on gastrointestinal motility.
the contractile state of smooth muscle in the gut. Enteric nerves contain a variety of neurotransmitters that may ultimately stimulate muscle contraction or induce relaxation, and the net effect of opioids on motor activity will depend on the neurotransmitter content of the nerve. Thus, an opiate-induced increase in motor activity may occur as a result of stimulation of an excitatory nerve or from inhibition of the release of a neurotransmitter that relaxes smooth muscle. An example of this is found in the small intestine of the dog (21). The administration of opiates, with the exception of dynorphin, results in stimulation of motor activity, presumably via μ or δ receptors. The action is blocked by the neuronal blocker tetrodotoxin and reduced by atropine, indicating that part of the effect on motility is due to the activation of cholinergic nerves (21). Since the response was not completely abolished by atropine, a more complex mechanism is suspected. More recent work has shown that motility in the canine small intestine is also under the tonic inhibitory effect of vasoactive intestinal peptide (VIP) (a neurotransmitter that relaxes smooth muscle), and that opiates suppress VIP release (22) via both μ and δ receptors (unpublished data). Thus, the observed net excitatory effect of opiates in this instance is due to both the activation of excitatory nerves and the suppression of inhibitory nerves.

The converse is also true: opiate-induced suppression of motor activity may result from the inhibition of an excitatory nerve or the activation of an inhibitory nerve (directly or indirectly by withdrawal of inhibitory modulation). The extent to which inhibitory or excitatory effects are seen will depend not only on the intrinsic properties of the opiate but also on whether the intestine is active or quiescent. Effects mediated by inhibitory nerves will only be apparent if the intestine is active, and no effect of the drug will be observed in the unstimulated state.

Presence of gastrointestinal disease. If a disease process alters the function or distribution of enteric nerves, it is reasonable to assume that the motility response to a drug such as an opiate will be altered. It has been shown, for example, that the motor response of the sigmoid colon to exogenous opiate is greatly exaggerated in the presence of active colitis (23). Although the mechanism underlying this observation has yet to be defined, it may reflect alterations in the distribution and content of enteric nerves associated with inflammatory bowel disease (24, 25). With respect to functional bowel disease, a similar phenomenon has been observed with colonic motor responses to cholecystokinin (26) and with the gastrocolic reflex (27), which is believed to involve opiate receptors (28). It follows that since a drug may induce quite different responses in healthy subjects than in patients with diseases, then the effects of the drug in patients are not necessarily predictable on the basis of its action in healthy subjects. The point will be illustrated later with trimethobutine.

Route of administration of opiate. Because of the wide distribution of opiate receptors that influence motility, the net effect of an administered opiate will also depend on ability to cross the blood brain barrier, the route of administration, and (in the case of in vitro experiments) the structural integrity of the tissue under study. Orally or intravenously administered drugs have access to the brain provided they cross the blood brain barrier. Drugs delivered close to the gut by local intra-arterial injection will primarily act on sites within the gut wall, including intrinsic nerves, muscle, blood vessels and mucosal cells. Drugs applied to muscle strip preparations in vitro will act on intrinsic nerves and muscle. Thus, it is not surprising to observe differences between the responses to central and peripheral administration of opiates and between motility responses to opiates administered in vivo and in vitro (29-31).

THE MECHANISMS OF ACTION OF TRIMETHOBUTINE ON MOTILITY

Overview: Results of radioligand binding studies are consistent with the hypothesis that trimethobutine is an opiate ligand that interacts with μ, δ and κ neural receptors with similar affinity (6). Taken in conjunction with data from physiological studies, these findings are consistent with the notion that trimethobutine behaves as a weak non-selective opiate agonist. On the basis of this profile, together with results of in vivo experiments in animals and in humans, the motility profile of trimethobutine (and hence its therapeutic potential) cannot be predicted on the basis of familiarity with traditional synthetic opiates such as codeine and morphine. Morphine and codeine are more selective for μ receptors, whereas trimethobutine interacts equally with μ, δ and κ receptors. Thus, while certain motility effects may be shared (eg, induction of motor complexes in the small intestine), other actions may be quite different (Table 2). From a clinical viewpoint, morphine and codeine slow transit and cause constipation, whereas trimethobutine appears to accelerate transit and may therefore be beneficial in the treatment of constipation due to colonic inertia.

Studies on the mechanism and locus of action of trimethobutine: In addition to the results of radioligand binding studies described above, there are several studies that describe the mechanisms of action of trimethobutine.

Action at extrinsic nerves. The inferior mesenteric ganglion serves to integrate nerve impulses from the central nervous system and peripheral nerves. It connects the central nervous system, the celiac plexus and the gut via the intermesenteric, hypogastric and lumbar colonic nerves, and thus is strategically located to influence gastrointestinal motility. Neurotransmission from preganglionic neurons is cholinergic but is modulated by opiates (17). Studies in the rabbit have shown that trimethobutine (1 μg/mL) exerts a bivalent effect on this ganglion, producing either inhibition of cholinergic nerve activity or initial excitation followed by late inhibition, without influencing resting membrane potential (32). Thus trimethobutine may influence motility (both initial and long term ex-
citation) by modulating sympathetic tone in the gut by virtue of its action on the inferior mesenteric ganglion.

Local actions of trimebutine in the gut. A recent study investigated the local actions of trimebutine on the gut wall by observing changes in circular muscle contraction following administration of the drug at various sites in the canine gut (33). Trimebutine was given in small boluses by intra-arterial injection in order to restrict its action to the region perfused by the artery. In the stomach, trimebutine, like other opiate agonists, had no excitatory effect in the quiescent gut, but inhibited motility induced by activation of local (postganglionic) cholinergic nerves. In the quiescent small intestine, trimebutine (100 µg) stimulated motility (Figure 1), and the effect was reduced by the neuronal blocker tetrodotoxin or by atropine, and was sensitive to naloxone. These results indicate that part of the trimebutine-induced excitatory effect on motility in the canine small intestine is due to opiate receptor-mediated activation of cholinergic nerves.

The atropine-insensitive component of the above described effect may be due to a direct effect of trimebutine on smooth muscle, to interactions with other nerves (eg, suppression of VIP release [22]), or to the ability of trimebutine to stimulate the release of motilin. When the small intestine was active (following local electrical field stimulation), trimebutine (0.1 to 100 µg) caused inhibition (33) (Figure 1). The effects of trimebutine on the canine stomach and small intestine resemble those obtained with met-enkephalin under the same experimental conditions, and are thus likely mediated by µ or δ opiate receptors (33,34).

The actions of trimebutine in the colon are more complex. Under the experimental conditions described above, trimebutine had no excitatory effect in the canine colon following close intra-arterial injection. When the colon was activated, trimebutine caused either weak inhibition or produced no effect at all (33). This profile is similar to that seen with the natural opiates met- or leu-enkephalin or dynorphin under the same conditions. Inhibition of colonic motility was most marked with dynorphin, suggesting that it is mediated primarily by κ receptors (34). These findings raise the possibility that the excitatory actions of opiates (including

---

**Figure 1** Examples of effects of trimebutine (T) on unstimulated (quiet) and field-stimulated intestine. Intra-arterial injections of T are shown by arrows, and doses are given in µg. **Top** Effects of T on quiet jejunum (J). Note the prolonged submaximal stimulation. **Bottom** Effects of T on field-stimulated ileum (I). Note the dose-dependent inhibition produced by different doses of T and the prolonged action of higher doses (from reference 34).
The Effect of Trimebutine on Gastrointestinal Motility in Humans

Actions on esophageal motility: In healthy fasted subjects, intravenous administration of trimebutine (50 mg) resulted in a twofold increase in lower esophageal sphincter pressure recorded manometrically using the pull-through technique (40). The response lasted approximately 13 mins and was compared to saline injection in a single-blind study of 20 subjects. The effect of trimebutine on lower esophageal sphincter pressure is different from that of morphine which, at intravenous doses of 8 mg, decreased sphincter pressure (41,42). Since morphine interacts with μ receptors, the trimebutine action is likely mediated via δ receptors, which have been identified in the opossum lower esophageal sphincter (43).

Although the effects of trimebutine on the esophageal body have not been described, a met-enkephalin analogue dose-dependently increased the amplitude, duration and propagation velocity of deglutition-induced contractions in humans (44). Taken together, these findings raise the possibility that trimebutine may be beneficial in reducing gastroesophageal reflux. In an uncontrolled study, administration of trimebutine elixir appeared to reduce gastroesophageal reflux in patients with endoscopically proven esophagitis (45). Trimebutine reduced the number and total duration of acid reflux episodes assessed by pH monitoring during a 3 h postprandial period in 10 patients. The effect of trimebutine occurred independently of the degree of esophagitis.

Effect on gastric motility and emptying: It is generally accepted that exogenous opiates decrease gastric emptying in healthy humans, illustrated in placebo controlled, double-blind, crossover study (47). In that study, oral administration of trimebutine (200 mg) significantly reduced the gastric emptying of liquid by approximately 19%. Gastric emptying was measured 1 h after trimebutine administration by a double sampling method using phenol red dye. The onset of action was 20 mins, and the maximum effect of trimebutine was observed at 40 mins. The therapeutic value of this effect is unclear, and it may even be detrimental in the application of the drug to treat gastroesophageal reflex.

Actions on small intestine: Several studies have shown that trimebutine affects intestinal motility in both the fasted and postprandial states (48,49). In the fasted state, intravenous administration of trimebutine (100 mg) induced aborally propagated motor complexes that resembled the intestinal component of spontaneous phase III interdigestive migrating motor complexes in terms of duration, propagation velocity and frequency of contraction (48). However, unlike spontaneous migrating motor complexes that occur first in the gastric antrum, trimebutine-induced complexes occurred only in the intestine, and antral activity was in fact, suppressed. This effect of trimebutine was abolished by intravenous infusion of naloxone (40 mg/kg/h), and was similar to that induced by administration of morphine (49), indicating the involvement of opiate μ receptors.

In another study in which intravenous trimebutine (100 mg) produced similar responses, the phase III-like motor complexes differed from spontaneous migrating motor complexes in that they were not accompanied by an increase in plasma motilin (50). Furthermore, others showed that administration of trimebutine suppressed plasma motilin concentrations in fasted healthy subjects, and that this effect was naloxone sensitive (48). These results differ from those reported in the dog, in which trimebutine-induced phase III-like activity was accompanied by an increase in plasma motilin concentration (37). These findings reflect...
Figure 2) The increases in postprandial colonic motility in the presence or absence of trimebutine in normal subjects and in patients with irritable bowel syndrome. The increase in motility is expressed as the mean percentage of increase above fasting values. Shown is the mean and SEM for each group, based on an analysis of eight normal subjects and seven patients with irritable bowel syndrome. Responses following trimebutine administration are shown by the hatched bars. The figure shows that trimebutine reduces the abnormal increase in postprandial motor activity in irritable bowel syndrome patients but does not affect motor activity in healthy controls (adapted from reference 56).

Species differences in the control of interdigestive motility by opiates in animals and humans.

In the fed state in humans, intravenous administration of trimebutine (100 mg) 40 mins after a 500 kcal meal interrupted postprandial motor activity with a motor complex that resembled the migrating motor complex of the interdigestive state (50). The action of trimebutine on postprandial intestinal motility may reflect the ability of that drug to prevent the postprandial increase in the hormones gastrin, insulin, gastric inhibitory polypeptide and glucagon, demonstrated recently in the dog (36).

The ability of trimebutine to stimulate propagated motor activity would suggest that the drug may be useful in accelerating transit through the small intestine. This was shown with the duodenal transit of liquid in healthy subjects using a dye dilution technique (51). The effect of trimebutine on small bowel transit may underlie its reported benefit in reducing duodenogastric alkaline reflux. In an open study, trimebutine was shown to reduce episodic alkaline reflux in patients with endoscopically proven bile reflux gastritis (52). In this study, gastric pH was monitored in 12 patients for 24 h before and after one month of oral trimebutine therapy (6 mg/kg/day). Trimebutine had no effect on gastric basal pH but significantly reduced the mean number and duration of episodes during which the gastric pH exceeded 4. This was associated with symptomatic improvement in eight of the 12 patients. Although the results were interpreted in light of an effect of trimebutine on gastroenteral motility, the extent to which the data were influenced by a direct effect on gastric acid secretion is not known.

The stimulatory effect of trimebutine in the intestine has also been applied to two conditions associated with slow transit in the small bowel: paralytic ileus and pseudo-obstruction. In patients with postoperative ileus, administration of intravenous trimebutine (50 to 300 mg) increased spiking activity in the small intestine, and the response was dose-dependent (53). Infusion of trimebutine for 12 h per day was also reported to accelerate the onset of the first passage of flatus postoperatively, in these patients, from a mean of 70 to 54 h.

In infants with pseudo-obstruction, characterized manometrically by extensive disruption of interdigestive motility in the small bowel, intravenous administration of trimebutine (3 mg/kg) induced phase III-like motor complexes which were propagated aborally (54). In two of the four patients studied, the administration of trimebutine was accompanied by the passage of flatus and a reduction in abdominal girth.

**Actions on the colon:** Rectosigmoid motility in normal subjects. In fasted (48) or fed (55) healthy human subjects, neither intravenous nor oral administration of trimebutine (100 mg) had an effect on motor activity measured manometrically in the sigmoid colon; this is in keeping with the actions of naturally occurring enkephalins in the dog (56). These findings again illustrate that trimebutine differs from other synthetic opiates such as morphine, codeine and loperamide, which invariably stimulate motor responses in the rectosigmoid (57,58). Because of regional differences, it should be emphasized that results obtained manometrically in the sigmoid colon may not necessarily reflect those recorded from more proximal regions of the colon. However, the absence of a trimebutine effect elsewhere in the healthy colon is supported by reports of unaltered colonic transit times following trimebutine administration in subjects with 'normal' colonic transit (59).

Rectosigmoid motility in patients with irritable bowel syndrome. In a study of irritable bowel syndrome patients, motor activity was recorded manometrically before and after a meal (900 to 1100 kcal) and then for 30 mins after the administration of intravenous trimebutine (50 mg) (60). Entry criteria included demonstration of an 'abnormal' colonic motor response to a meal, based on the authors' prior experience with 20 normal subjects. Of 16 irritable bowel syndrome patients entered, seven
were classified as exhibiting 'hypomotility' with a poor response to meals, and seven were classified into a 'hypermotility' group exhibiting an exaggerated meal response. In irritable bowel syndrome patients with basal 'hypomotility', trimebutine significantly increased the postprandial motor response, whereas in the patients with basal and postprandial 'hypermotility', trimebutine significantly reduced motor activity.

The suggestion of a modulating effect of trimebutine on colonic motor activity was further supported by a recent placebo controlled, crossover study in which rectosigmoid motility was recorded manometrically in nine constipated irritable bowel syndrome patients and 11 normal subjects (55). Trimebutine was administered in a single oral 200 mg dose 20 mins before the ingestion of a meal. Following placebo ingestion, the rectosigmoid motor response to the meal (gastrocolic reflex) was significantly larger in the irritable bowel syndrome group compared to controls (increases over baseline of 49.1% versus 21.9%). Administration of trimebutine attenuated the meal-induced response in the irritable bowel syndrome group (reducing it from 49.1 to 28.9%), bringing it into a range closer to that to normals (Figure 2). In contrast, the opposite trend was observed in normal subjects in whom trimebutine caused a small, statistically insignificant increase in the postprandial response (from 21.9 to 23.9%). Since this was an acute study, symptoms were not assessed.

**Transit studies:** In constipated irritable bowel syndrome patients, oral administration of trimebutine (200 mg tid) for eight weeks significantly improved abdominal pain and constipation, superior to placebo in a double-blind crossover study (3). These findings were accompanied by a significant decrease in whole gut transit time of radiopaque markers. Since the colon is a major determinant of gut transit, these studies suggest an effect of trimebutine on colonic motility in constipated irritable bowel syndrome patients.

Similar results were obtained in another double-blind, placebo controlled, crossover study in which irritable bowel syndrome patients with abdominal distension, pain and constipation were given trimebutine or placebo for one month, and each treatment was separated by a one week washout period (59). The study group contained 12 patients with slow colonic transit, and 12 patients with normal transit times of less than 40 h, assessed by the passage of radiopaque markers. All patients had failed to improve on fibre supplements prior to entering the study. Trimebutine therapy caused a significant reduction in colonic transit time from 105±19 to 60±11 h (P<0.015) in the slow transit group, without a significant change occurring in the group with normal colonic transit times. Symptoms of abdominal distension and pain relieved by defeation were significantly improved in both groups, but there was no change in stool frequency compared to placebo.

**Colonic myoelectrical activity:** The field of recording and interpreting myoelectrical signals from the human colon in vivo is fraught with difficulties and conflicting data. There is agreement between some groups that myoelectrical activity may be described in terms of long and short spike bursts (61). Short spike bursts last about 3 s, are localized, seldom propagate, and are common in the proximal colon. They serve to retard the fecal stream and prolong transit; they are found in increased numbers in constipated humans (62) and experimentally constipated dogs (63). Long spike bursts last about 21 s, may propagate ad- or aborally, and are found mainly in the distal colon (62).

Placebo controlled studies on the action of trimebutine on colonic myoelectrical activity in irritable bowel syndrome patients have yielded conflicting results. In one study, trimebutine had no effect on short spike bursts in either constipated irritable bowel syndrome patients nor in those with diarrhea (64); trimebutine did reduce the duration of long spike bursts in both subgroups of patients, but the therapeutic significance of this finding is not apparent. However, in another study (59), trimebutine significantly increased the number of propagated spike bursts in patients with constipation. Since this type of activity has been positively correlated with propulsive movement in the colon, the finding is in keeping with the documented effects of trimebutine in accelerating colonic transit in irritable bowel syndrome patients with constipation (3,59).

In an uncontrolled study of the action of trimebutine on rectosigmoid activity in normal subjects and irritable bowel syndrome patients, trimebutine appeared to exhibit a 'normalizing' effect (65). Recordings were taken from the region of the rectosigmoid junction where the authors claimed that spiking activity remains relatively constant at a frequency of 0 to 2 spike bursts/min. In five normal subjects, intravenous trimebutine (100 mg) had no substantial effect on electrical activity, but stimulated spike bursts in one asymptomatic subject who had no discernible basal activity. In seven irritable bowel syndrome patients with increased basal spiking activity, trimebutine appeared to decrease activity. An additional 11 irritable bowel syndrome patients had normal basal spiking activity, and in eight of these, trimebutine had no effect but the drug increased spike bursts in the remaining three patients. Since no information was provided regarding the clinical status of the trimebutine responders and nonresponders, and because the study was uncontrolled, the data are of limited use, although they may provide an example of a bivalent or 'normalizing' effect of trimebutine on human gastrointestinal motility.

**Synthesis:** In balance, the results of studies on colonic transit, motility and myoelectrical activity are consistent with the view that trimebutine accelerates slow transit in the colon by encouraging propagated motility in the proximal colon and reducing nonpropagated activity in the sigmoid region. The clinical extrapolation of these data is that trimebutine may be useful in treating constipation due to colonic inertia.

**REFERENCES**

15. Stewart J, Weisbrod NW, Burks TF. Central and peripheral actions of morphine on intestinal transit.

J Pharmacol Exp Ther 1978;205:547-55.
43. Rattan S, Goyal RK. Identification and localization of opioid receptors in the opossum lower esophageal


